Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer…
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer…
Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) announced it has executed a memorandum of understanding dated March 16, 2026 with…
Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline…
Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart…
Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital…
ParaZero Technologies (NASDAQ: PRZO) announced it has entered into a definitive agreement for a registered direct offering with a single institutional investor…
OptimumBank Holdings (NYSE American: OPHC) announced it has been ranked No. 49 in the S&P Global Market Intelligence 2025 Top 100…
Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the…
This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF) reported…
This article has been disseminated on behalf of McEwen Inc. and may include paid advertising. McEwen (NYSE: MUX) (TSX: MUX) reported a mineral resource estimate for…